Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
ANIP 
ANI Pharmaceuticals Inc (ANIP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
01/07/2026: ANIP (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $109.25
1 Year Target Price $109.25
| 3 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 34.57% | Avg. Invested days 47 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 01/07/2026 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.74B USD | Price to earnings Ratio 48.42 | 1Y Target Price 109.25 |
Price to earnings Ratio 48.42 | 1Y Target Price 109.25 | ||
Volume (30-day avg) 6 | Beta 0.51 | 52 Weeks Range 52.73 - 99.50 | Updated Date 01/6/2026 |
52 Weeks Range 52.73 - 99.50 | Updated Date 01/6/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 1.6 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 4.91% | Operating Margin (TTM) 10.2% |
Management Effectiveness
Return on Assets (TTM) 2.49% | Return on Equity (TTM) 8.66% |
Valuation
Trailing PE 48.42 | Forward PE 9.21 | Enterprise Value 2110235116 | Price to Sales(TTM) 2.1 |
Enterprise Value 2110235116 | Price to Sales(TTM) 2.1 | ||
Enterprise Value to Revenue 2.55 | Enterprise Value to EBITDA 12.9 | Shares Outstanding 22458168 | Shares Floating 18895277 |
Shares Outstanding 22458168 | Shares Floating 18895277 | ||
Percent Insiders 9.99 | Percent Institutions 97.62 |
About ANI Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Baudette, MN, United States | ||
IPO Launch date 2000-05-05 | President, CEO & Director Mr. Nikhil Lalwani | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 897 | |
Full time employees 897 | |||
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. It markets, sells, and distributes its products through wholesalers, retail market chains, distributors and specialty pharmacies, group purchasing organizations, specialty pharmacies, hospitals, clinics, and physicians. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.